Are premium IOLs set to break out?
The market forces that have held them back may be changing.
By Jeffrey S. Eisenberg
Caught in the middle: glaucoma and cataract
A stepped surgical approach could be the answer.
By E. Randy Craven, MD
How intracameral antibiotics can reduce postoperative drug costs
Vancomycin-ceftazidime may be the protocol of choice, but other options have proven efficacious and safe.
By James P. Gills, MD
Keep the message real for FSL cataract surgery
Shape promotional claims with an eye on professional and regulatory guidelines.
By Kevin J. Corcoran, COE, CPC, CPMA, FNAO
Quick Hits
OTX starts key trial, obtains new funding; High court permits "pay-for-delay" lawsuits; Update on MOC requirements; An eyedrop treatment for wet AMD; and more
Teacher, teacher: Staff and physicians' roles in positioning premium IOLs
Education is key in in cataract surgery with astigmatism. Biometry is a teaching tool.
By R. Bruce Wallace III, MD, FACS
The emerging challenge: post-refractive cataract patients
Accurate IOL calculation is the primary issue.
By Jerry Helzner, contributing editor
Tips for improving cataract outcomes
Meet the demands of patients and payers as they track quality measures.
By Jessica Ciralsky, MD, Edward
Viewpoint
To drop or not to drop?